Last reviewed · How we verify
DAC N-055
At a glance
| Generic name | DAC N-055 |
|---|---|
| Sponsor | Waisenmedizin e. V. Promoting Access to Essential Medicine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul (PHASE2, PHASE3)
- Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |